In the Phase III LITESPARK-011 trial, the FDA approved Merck’s Welireg (belzutifan) plus Eisai-partnered Lenvima (lenvatinib) for advanced clear-cell renal cell carcinoma after prior PD-(L)1 therapy, after the regimen improved median progression-free survival to 14.6 months vs. 10.6 months with cabozantinib and cut the risk of progression or death by 26%. The study randomized 747 patients, and while objective responses were higher with the combo (53% vs. 40%), the final overall survival analysis was not statistically significant.

Why It Matters To Oncology

• The approval moves Welireg earlier in advanced RCC, expanding beyond its 2023 label for patients previously treated with both PD-(L)1 and VEGF-targeted therapy.

• It gives clinicians a new post-immunotherapy option in clear-cell RCC built around HIF-2α inhibition plus VEGF blockade.

• The lack of a statistically significant overall survival benefit may shape uptake, especially in a crowded RCC treatment landscape.

The Financials

• The decision strengthens Merck’s kidney cancer franchise and adds another commercial foothold for Welireg just three months after its adjuvant expansion.

• It also supports Lenvima’s lifecycle in RCC through Merck and Eisai’s partnership, with a new labeled use in a defined post-IO setting.

• Longer-term revenue potential could be tempered if more patients receive Welireg earlier in the adjuvant setting.

What They're Saying

• Michael Atkins of Georgetown Lombardi said after the June adjuvant approval that many patients may not go on to receive Welireg in metastatic disease because they could already have had the drug earlier.

• That view underscores a key clinical-commercial tension: earlier use can expand a brand while narrowing later-line opportunity.

• For prescribers, the main near-term debate is likely to center on sequencing after prior immunotherapy and against established VEGF TKI options.

What's Next

• Clinicians will watch how the Welireg-Lenvima regimen is positioned in treatment pathways for post-PD-(L)1 advanced ccRCC.

• Adoption may depend on how physicians weigh stronger progression-free survival and response data against the absence of a significant overall survival result.

• Another key question is whether broader adjuvant use of Welireg plus pembrolizumab will reduce the pool of patients eligible for this second-line combination.